Lisinopril vs Amlodipine Side Effects: A Head-to-Head Comparison

How These Two Drugs Work Differently

Lisinopril and amlodipine both reduce blood pressure effectively, but through entirely separate mechanisms. That mechanistic split explains why their side-effect profiles barely overlap.

Lisinopril: ACE Inhibitor Mechanism

Lisinopril blocks angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II. This reduces arterial vasoconstriction and aldosterone secretion. A secondary consequence: ACE also degrades bradykinin, so blocking ACE causes bradykinin to accumulate in the airways. That buildup is the direct biochemical cause of the dry cough and, in rare cases, angioedema that define ACE inhibitor therapy 1.

Amlodipine: Calcium Channel Blocker Mechanism

Amlodipine blocks L-type calcium channels in vascular smooth muscle cells. Less intracellular calcium means less contraction, which means vasodilation. The drug is highly selective for vascular tissue over cardiac tissue, so it lowers peripheral resistance without significantly depressing heart rate or contractility. Peripheral edema from amlodipine is not caused by fluid retention. It results from precapillary arteriolar dilation without matching venodilation, creating a hydrostatic pressure gradient that pushes fluid into interstitial tissue 2.

What the Landmark Trials Found

No single randomized trial directly compared lisinopril to amlodipine as its primary research question. The two largest datasets come from ALLHAT and ASCOT-BPLA, both of which included these drug classes as separate arms tested against other comparators.

ALLHAT: Lisinopril vs Chlorthalidone

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT, 2002) randomized 33,357 high-risk hypertensive patients aged 55 and older to chlorthalidone, amlodipine, or lisinopril. The lisinopril arm (N=9,054) showed equivalent primary coronary heart disease outcomes to chlorthalidone but had a 15% higher rate of stroke (RR 1.15, 95% CI 1.02 to 1.30) and a 10% higher rate of combined cardiovascular disease 1. Discontinuation rates were higher in the lisinopril group, partly driven by cough and angioedema. Black participants had notably worse blood pressure control on lisinopril, with 6/5 mmHg higher systolic/diastolic readings than the chlorthalidone group at year 5.

ASCOT-BPLA: Amlodipine vs Atenolol

The Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Lowering Arm (ASCOT-BPLA, 2005) assigned 19,257 patients to amlodipine-based or atenolol-based regimens. The amlodipine arm showed 23% fewer strokes (HR 0.77, 95% CI 0.66 to 0.89, P=0.0003) and 16% fewer cardiovascular events. The trial was stopped early because of a clear benefit favoring amlodipine. Peripheral edema was the dominant amlodipine complaint, but overall discontinuation rates were lower than in the atenolol arm 2.

Cross-Trial Observations

Across both trials, amlodipine-based regimens produced slightly lower mean blood pressures than ACE-inhibitor-based regimens. A 2003 ALLHAT subanalysis noted that the amlodipine arm (N=9,048) had peripheral edema in 32.4% of participants at some point during follow-up, versus 12.7% in the lisinopril arm 1. Cough was documented in 1.8% of the lisinopril arm as a cause for switching, though self-reported cough rates in observational studies run much higher.

Lisinopril Side Effects in Detail

The side-effect burden of lisinopril is dominated by two related phenomena: cough and angioedema. Both trace back to bradykinin accumulation.

The ACE Inhibitor Cough

Dry, persistent, nonproductive cough occurs in 5%, 35% of patients on ACE inhibitors, depending on the population studied. Women are affected roughly twice as often as men. East Asian populations report cough rates at the higher end of that range. The cough typically appears within 1 to 6 months of starting therapy and resolves within 1 to 4 weeks of discontinuation 3. It is not dose-dependent. A patient who coughs on lisinopril 5 mg will almost certainly cough on 40 mg. Switching to an angiotensin receptor blocker (ARB) resolves the cough in about 95% of cases.

Angioedema

Angioedema on ACE inhibitors affects 0.1%, 0.7% of users, with a 3-to-4-fold higher incidence in Black patients 4. It presents as rapid swelling of the lips, tongue, face, or larynx. Laryngeal involvement can be life-threatening. Angioedema can appear at any point during therapy, even years after initiation. Dr. Nancy Brown, a clinical pharmacologist at Vanderbilt University Medical Center, has stated: "ACE inhibitor angioedema is unpredictable in onset and does not follow a dose-response relationship, which makes it fundamentally different from allergic angioedema."

Hyperkalemia

Lisinopril reduces aldosterone-mediated potassium excretion, raising serum potassium levels. In patients with normal renal function, this effect is usually clinically insignificant. In patients with chronic kidney disease (eGFR <45 mL/min/1.73 m²), diabetes, or concurrent use of potassium-sparing diuretics, the risk becomes meaningful. The 2017 ACC/AHA hypertension guideline recommends checking serum potassium within 2 to 4 weeks of starting or up-titrating an ACE inhibitor 5.

Other Reported Effects

Dizziness, headache, and fatigue are reported by 3%, 6% of lisinopril users in clinical trials, though rates are often similar to placebo. Hypotension on first dose is possible, particularly in volume-depleted patients or those on high-dose diuretics. Acute kidney injury can occur in patients with bilateral renal artery stenosis.

Amlodipine Side Effects in Detail

Amlodipine's side-effect profile centers on the vascular consequences of arterial vasodilation.

Peripheral Edema

This is the most frequent reason patients stop amlodipine. Dose-dependent ankle and pedal edema occurs in approximately 1.8% of patients on 5 mg and 10.8% on 10 mg 6. The edema is not caused by sodium retention and does not respond to diuretics. It is caused by the differential dilation of precapillary arterioles without corresponding postcapillary venodilation. Elevating the legs helps. Adding an ARB or ACE inhibitor to amlodipine partially counteracts the edema by dilating the venous side, which is one reason combination pills (amlodipine/benazepril, amlodipine/olmesartan) exist.

Flushing and Headache

Facial flushing affects 2%, 3% of amlodipine users and typically appears in the first 1 to 2 weeks, diminishing as the body adjusts. Headache occurs in approximately 7.3% of patients at 10 mg, compared to 7.8% on placebo in some trials, making it difficult to attribute solely to the drug 6.

Gingival Hyperplasia

A class effect of calcium channel blockers, gingival overgrowth has been reported in 1%, 3% of amlodipine users, typically after 3 to 6 months. Good oral hygiene reduces the risk. If it occurs, switching drug class is the definitive treatment. The 2017 American Academy of Periodontology noted that "drug-influenced gingival enlargement from calcium channel blockers is the second most common medication-associated gingival condition after phenytoin."

Fatigue and Dizziness

Dizziness affects 1%, 3% of amlodipine users. Severe fatigue is reported occasionally, but controlled trial data show rates close to placebo. Unlike beta-blockers, amlodipine does not commonly cause exercise intolerance or sexual dysfunction.

Reflex Tachycardia

Amlodipine's long half-life (30 to 50 hours) produces smooth plasma levels that minimize reflex tachycardia. Short-acting dihydropyridines like immediate-release nifedipine caused significant heart rate increases, but this is rarely clinically relevant with amlodipine.

Side-by-Side Comparison Table

| Side Effect | Lisinopril | Amlodipine | |---|---|---| | Dry cough | 5%, 35% | Rare (<1%) | | Peripheral edema | Uncommon | 1.8%, 10.8% (dose-dependent) | | Angioedema | 0.1%, 0.7% | Not associated | | Hyperkalemia | Yes (especially with CKD) | No | | Gingival hyperplasia | No | 1%, 3% | | Flushing | Rare | 2%, 3% | | Headache | 3%, 6% | 3%, 7% | | Dizziness | 3%, 6% | 1%, 3% | | First-dose hypotension | Possible | Rare (slow onset) | | Reflex tachycardia | No | Minimal | | Pregnancy risk | Black-box warning | Contraindicated |

Who Should Choose Which Drug

The choice between these two agents often depends more on the patient's comorbidities and tolerability than on raw efficacy data.

When Lisinopril Has the Edge

Lisinopril is preferred in patients with heart failure with reduced ejection fraction (HFrEF), diabetic nephropathy, or proteinuric chronic kidney disease. ACE inhibitors reduce proteinuria by approximately 30%, 35% beyond what blood pressure lowering alone would predict 7. The 2017 ACC/AHA guideline lists ACE inhibitors as a compelling indication in these populations 5. Patients who do not develop cough on an ACE inhibitor often remain on one for decades without issues.

When Amlodipine Has the Edge

Amlodipine is preferred in patients who develop ACE inhibitor cough, Black patients who may have reduced blood pressure response to ACE inhibitors as monotherapy, patients with Raynaud phenomenon, and older adults with isolated systolic hypertension. ASCOT-BPLA showed particular benefit for stroke prevention with the amlodipine-based regimen 2. Amlodipine also has no effect on serum potassium, making it safer in patients already at risk for hyperkalemia.

Combination Therapy

Many patients end up on both drugs. The 2018 ESC/ESH hypertension guideline recommends starting most patients on two-drug combination therapy, and an ACE inhibitor plus a calcium channel blocker is one of the preferred pairings 8. Combining the two partially offsets amlodipine's pedal edema (the ACE inhibitor dilates venous capacitance vessels) while preserving the renal benefits of ACE inhibition. The ACCOMPLISH trial (N=11,506) showed that benazepril/amlodipine reduced cardiovascular events by 19.6% versus benazepril/hydrochlorothiazide (HR 0.80, 95% CI 0.72 to 0.90, P<0.001) 9.

Special Populations and Safety Signals

Pregnancy

Both drugs are contraindicated. Lisinopril carries an FDA black-box warning for fetal toxicity, particularly renal dysgenesis and oligohydramnios when used in the second and third trimesters 10. Amlodipine has less human data but showed embryotoxicity in animal studies at high doses. Women of childbearing potential on either drug should use reliable contraception.

Older Adults

Both drugs are considered appropriate first-line agents in older adults by the 2017 ACC/AHA guideline. Lisinopril's first-dose hypotension risk warrants starting at 5 mg in patients over 75 or those on diuretics. Amlodipine's pedal edema may be misattributed to heart failure in this population, leading to unnecessary workups.

Chronic Kidney Disease

Lisinopril slows CKD progression in proteinuric disease but requires potassium monitoring. Amlodipine has no direct renal-protective effect but also does not worsen renal function. In advanced CKD (eGFR <30), the risk-benefit ratio shifts, and nephrologist input is warranted before starting or continuing either drug.

Monitoring Requirements

Lisinopril demands more laboratory monitoring than amlodipine. Baseline serum creatinine, potassium, and eGFR should be checked before initiation and rechecked within 2 to 4 weeks. Annual monitoring is standard for stable patients. If potassium exceeds 5.5 mEq/L or creatinine rises more than 30% from baseline, the ACC/AHA guideline recommends dose reduction or discontinuation 5.

Amlodipine requires no routine laboratory monitoring. Blood pressure follow-up and clinical assessment for edema are sufficient. A dental exam may be reasonable at 6 months for patients who develop gingival tenderness.

Switching Between Lisinopril and Amlodipine

Switching from lisinopril to amlodipine (or vice versa) does not require a taper. Lisinopril can be stopped and amlodipine started the next day at 5 mg, with titration to 10 mg after 7 to 14 days if blood pressure remains above target. When switching in the opposite direction, start lisinopril at 10 mg (or 5 mg in older adults) and check potassium and creatinine within 2 to 4 weeks.

Dr. George Bakris, professor of medicine at the University of Chicago and director of the AHA Comprehensive Hypertension Center, has noted: "The most common reason for switching from an ACE inhibitor to a CCB is cough. The most common reason for switching from a CCB to an ACE inhibitor is edema. Neither side effect is dangerous, but both significantly affect quality of life."

Cost and Access Considerations

Both lisinopril and amlodipine are available as generics with a typical 30-day cash price of $4, $15 at major pharmacies. Neither drug requires prior authorization from commercial insurance or Medicare Part D. Both appear on the $4 generic lists at Walmart, Costco, and most chain pharmacies. Cost is rarely the deciding factor between these two medications.

The combination pill amlodipine/benazepril (Lotrel generic) costs $10, $30 per month at most pharmacies, offering a convenient single-pill option for patients who benefit from dual therapy 11.

The Bottom Line

Lisinopril's worst side effects (cough, angioedema, hyperkalemia) are mechanistically tied to bradykinin and RAAS blockade. Amlodipine's worst side effects (edema, flushing, gingival changes) stem from arteriolar vasodilation. In ALLHAT, lisinopril-arm participants were more likely to discontinue therapy than those on amlodipine. In ASCOT-BPLA, amlodipine produced better cardiovascular outcomes than the atenolol-based comparator. For patients who tolerate both drugs, the ACCOMPLISH trial demonstrated that using them together reduced major cardiovascular events by roughly 20% compared to ACE inhibitor plus diuretic 9. Prescribers should select based on comorbidities first, then adjust for tolerability. Check potassium at 2 to 4 weeks if starting lisinopril; check ankles at 2 to 4 weeks if starting amlodipine.